Loading…
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment...
Saved in:
Published in: | Clinical practice and epidemiology in mental health 2021, Vol.17 (1), p.307-314 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73 |
---|---|
cites | cdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73 |
container_end_page | 314 |
container_issue | 1 |
container_start_page | 307 |
container_title | Clinical practice and epidemiology in mental health |
container_volume | 17 |
creator | Giesinger, Johannes M La Nasa, Giorgio Sparano, Francesco Angermeyer, Matthias Morelli, Emanuela Mulas, Olga Efficace, Fabio Caocci, Giovanni |
description | Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies. |
doi_str_mv | 10.2174/1745017902117010307 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2653268042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</originalsourceid><addsrcrecordid>eNptUUtP3DAQtipQodv-gkrIRy5p7fiV5YCEVlCQtuJRerYce9w1cuJtnAWlB357vYIiKnEYzeibmW8eH0KfKflSU8W_FhOEqjmpKVWEEkbUO7S_RastvPMq3kMfcr4jhDW8Zu_RHhOcc0WaffR4DiaOq-oGohnB4euNiWGccPJ4GTzgk5wh5w76EYceX5kxlDDjhzCu8PcJYnJTXkeTx2Dxj6l3Q-ogH-HT--Cgt4B9AfCN6V3qwp_Cv4ihD9ZEfDsEE_NHtOuLg0_PfoZ-np3eLs6r5eW3i8XJsrKsJqpSjVDOk1Y6wlpWLnWg5gW0CqgAJ4lriZBESiG9cb6RVkjua8pcK-fcKDZDx0-8603bgbPliMFEvR5CZ4ZJJxP0_5k-rPSvdK-beSO44oXg8JlgSL83kEfdhWwhRtND2mRdS8Fq2ZDy3xliT6V2SDkP4F_GUKK3yuk3lCtdB683fOn5JxX7C0hNlgk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2653268042</pqid></control><display><type>article</type><title>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</title><source>Bentham Science Publishers OA</source><source>PubMed Central</source><creator>Giesinger, Johannes M ; La Nasa, Giorgio ; Sparano, Francesco ; Angermeyer, Matthias ; Morelli, Emanuela ; Mulas, Olga ; Efficace, Fabio ; Caocci, Giovanni</creator><creatorcontrib>Giesinger, Johannes M ; La Nasa, Giorgio ; Sparano, Francesco ; Angermeyer, Matthias ; Morelli, Emanuela ; Mulas, Olga ; Efficace, Fabio ; Caocci, Giovanni</creatorcontrib><description>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.</description><identifier>ISSN: 1745-0179</identifier><identifier>EISSN: 1745-0179</identifier><identifier>DOI: 10.2174/1745017902117010307</identifier><identifier>PMID: 35444708</identifier><language>eng</language><publisher>United Arab Emirates: Bentham Science Publishers</publisher><subject>Clinical Practice Epidemiology in Mental Health</subject><ispartof>Clinical practice and epidemiology in mental health, 2021, Vol.17 (1), p.307-314</ispartof><rights>2021 Giesinger et al.</rights><rights>2021 Giesinger . 2021 Giesinger</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</citedby><cites>FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985474/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985474/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3740,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35444708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giesinger, Johannes M</creatorcontrib><creatorcontrib>La Nasa, Giorgio</creatorcontrib><creatorcontrib>Sparano, Francesco</creatorcontrib><creatorcontrib>Angermeyer, Matthias</creatorcontrib><creatorcontrib>Morelli, Emanuela</creatorcontrib><creatorcontrib>Mulas, Olga</creatorcontrib><creatorcontrib>Efficace, Fabio</creatorcontrib><creatorcontrib>Caocci, Giovanni</creatorcontrib><title>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</title><title>Clinical practice and epidemiology in mental health</title><addtitle>Clin Pract Epidemiol Ment Health</addtitle><description>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.</description><subject>Clinical Practice Epidemiology in Mental Health</subject><issn>1745-0179</issn><issn>1745-0179</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNptUUtP3DAQtipQodv-gkrIRy5p7fiV5YCEVlCQtuJRerYce9w1cuJtnAWlB357vYIiKnEYzeibmW8eH0KfKflSU8W_FhOEqjmpKVWEEkbUO7S_RastvPMq3kMfcr4jhDW8Zu_RHhOcc0WaffR4DiaOq-oGohnB4euNiWGccPJ4GTzgk5wh5w76EYceX5kxlDDjhzCu8PcJYnJTXkeTx2Dxj6l3Q-ogH-HT--Cgt4B9AfCN6V3qwp_Cv4ihD9ZEfDsEE_NHtOuLg0_PfoZ-np3eLs6r5eW3i8XJsrKsJqpSjVDOk1Y6wlpWLnWg5gW0CqgAJ4lriZBESiG9cb6RVkjua8pcK-fcKDZDx0-8603bgbPliMFEvR5CZ4ZJJxP0_5k-rPSvdK-beSO44oXg8JlgSL83kEfdhWwhRtND2mRdS8Fq2ZDy3xliT6V2SDkP4F_GUKK3yuk3lCtdB683fOn5JxX7C0hNlgk</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Giesinger, Johannes M</creator><creator>La Nasa, Giorgio</creator><creator>Sparano, Francesco</creator><creator>Angermeyer, Matthias</creator><creator>Morelli, Emanuela</creator><creator>Mulas, Olga</creator><creator>Efficace, Fabio</creator><creator>Caocci, Giovanni</creator><general>Bentham Science Publishers</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2021</creationdate><title>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</title><author>Giesinger, Johannes M ; La Nasa, Giorgio ; Sparano, Francesco ; Angermeyer, Matthias ; Morelli, Emanuela ; Mulas, Olga ; Efficace, Fabio ; Caocci, Giovanni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Practice Epidemiology in Mental Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giesinger, Johannes M</creatorcontrib><creatorcontrib>La Nasa, Giorgio</creatorcontrib><creatorcontrib>Sparano, Francesco</creatorcontrib><creatorcontrib>Angermeyer, Matthias</creatorcontrib><creatorcontrib>Morelli, Emanuela</creatorcontrib><creatorcontrib>Mulas, Olga</creatorcontrib><creatorcontrib>Efficace, Fabio</creatorcontrib><creatorcontrib>Caocci, Giovanni</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical practice and epidemiology in mental health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giesinger, Johannes M</au><au>La Nasa, Giorgio</au><au>Sparano, Francesco</au><au>Angermeyer, Matthias</au><au>Morelli, Emanuela</au><au>Mulas, Olga</au><au>Efficace, Fabio</au><au>Caocci, Giovanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</atitle><jtitle>Clinical practice and epidemiology in mental health</jtitle><addtitle>Clin Pract Epidemiol Ment Health</addtitle><date>2021</date><risdate>2021</risdate><volume>17</volume><issue>1</issue><spage>307</spage><epage>314</epage><pages>307-314</pages><issn>1745-0179</issn><eissn>1745-0179</eissn><abstract>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.</abstract><cop>United Arab Emirates</cop><pub>Bentham Science Publishers</pub><pmid>35444708</pmid><doi>10.2174/1745017902117010307</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1745-0179 |
ispartof | Clinical practice and epidemiology in mental health, 2021, Vol.17 (1), p.307-314 |
issn | 1745-0179 1745-0179 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985474 |
source | Bentham Science Publishers OA; PubMed Central |
subjects | Clinical Practice Epidemiology in Mental Health |
title | Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A49%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health-Related%20Quality%20of%20Life%20Assessment%20in%20Patients%20with%20Myelodysplastic%20Syndromes:%20Evidence%20from%20Randomized%20Clinical%20Trials&rft.jtitle=Clinical%20practice%20and%20epidemiology%20in%20mental%20health&rft.au=Giesinger,%20Johannes%20M&rft.date=2021&rft.volume=17&rft.issue=1&rft.spage=307&rft.epage=314&rft.pages=307-314&rft.issn=1745-0179&rft.eissn=1745-0179&rft_id=info:doi/10.2174/1745017902117010307&rft_dat=%3Cproquest_pubme%3E2653268042%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2653268042&rft_id=info:pmid/35444708&rfr_iscdi=true |